Study Links Untreated Sleep Apnea to Increased Parkinson’s Risk

A landmark study has established a significant connection between untreated sleep apnea and an elevated risk of developing Parkinson’s disease, adding to growing evidence that sleep disorders may contribute to neurological conditions.

The research, which tracked patients over several years, found that individuals with diagnosed but untreated sleep apnea showed substantially higher rates of Parkinson’s disease compared to both the general population and patients receiving treatment for their sleep disorder.

“This study highlights the potential neurological consequences of a common sleep problem that many people dismiss as mere snoring or poor sleep,” said Dr. Elizabeth Chen, a neurologist not involved with the research but familiar with its findings. “We’ve long known about sleep apnea’s cardiovascular risks, but its neurological implications deserve equal attention.”

Sleep apnea affects an estimated 22 million Americans, with many cases remaining undiagnosed. The condition, characterized by repeated breathing interruptions during sleep, causes oxygen deprivation and sleep fragmentation that researchers believe may accelerate neurodegeneration through increased inflammation and oxidative stress.

The connection between sleep disorders and neurological health has gained increasing attention in recent years. Earlier research has already established links between poor sleep quality and conditions like Alzheimer’s disease, but this new study represents one of the largest examinations specifically focused on Parkinson’s risk.

“The brain’s waste clearance system operates primarily during deep sleep,” explained Dr. Michael Thorton, a sleep medicine specialist at Northwestern University. “When sleep is repeatedly disrupted, as happens with apnea, this cleaning process is compromised, potentially allowing harmful proteins to accumulate.”

The findings carry particular significance for middle-aged and older adults, demographics where both sleep apnea and Parkinson’s disease become more prevalent. Men over 50 with sleep apnea may face particularly elevated risks, according to the study’s demographic analysis.

Healthcare providers are now emphasizing the importance of sleep apnea screening and treatment as a potential preventive measure against neurodegenerative diseases. Continuous positive airway pressure (CPAP) therapy, the standard treatment for sleep apnea, showed protective effects in the study population, with treated patients demonstrating Parkinson’s rates closer to those without sleep disorders.

“We need to start viewing quality sleep not as a luxury but as a fundamental health necessity,” said Dr. Sarah Jenkins, director of the Sleep Disorders Center at Mayo Clinic. “These findings suggest that diagnosing and treating sleep apnea could potentially serve as a modifiable risk factor for Parkinson’s disease.”

The study also noted that certain populations face barriers to diagnosis and treatment. Rural communities often lack access to sleep specialists and testing facilities, while lower-income patients may struggle with insurance coverage for sleep studies and CPAP equipment, which can cost thousands of dollars without adequate coverage.

Public health experts are calling for expanded screening protocols and improved insurance coverage for sleep disorders in light of these findings. The potential healthcare cost savings from preventing or delaying neurodegenerative diseases could be substantial, given that Parkinson’s disease treatment costs an estimated $52 billion annually in the United States alone.

“If we can identify high-risk individuals earlier and implement effective sleep interventions, we may have an opportunity to alter the trajectory of neurological disease,” noted Dr. Jenkins. “This represents a significant shift in how we approach both sleep medicine and neurology.”

Researchers emphasize that while the association between sleep apnea and Parkinson’s is robust, more work is needed to establish causality and determine the exact mechanisms involved. Several large-scale clinical trials are now underway to investigate whether early intervention for sleep disorders can measurably reduce the incidence of neurodegenerative conditions.

For now, experts recommend that anyone experiencing symptoms of sleep apnea—including loud snoring, witnessed breathing pauses during sleep, excessive daytime sleepiness, or morning headaches—should discuss screening options with their healthcare provider.